MOLNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
MOLECULAR PARTNERS AG
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 12, 2026
$3.66+0.10 (+2.81%)
Close on Oct 19, 2026
MOLECULAR PARTNERS AG revenue by segment
By business segment
By product or service
By region
| Revenue | Q2 25 | Q2 24 | Q2 23 | Q2 22 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Switzerland | CHF 0 | CHF 1.55M | CHF 415.00K | CHF 2.90M | – | -100.0% |
| United States | – | – | CHF 0 | CHF 8.85M | – | – |
From the segment and revenue-disaggregation notes of Molecular Partners's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.